# Alessandro Serretti

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/9270708/alessandro-serretti-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 691<br/>papers
 25,313<br/>citations
 73<br/>h-index
 129<br/>g-index

 831<br/>ext. papers
 29,543<br/>ext. citations
 4.8<br/>avg, IF
 7.27<br/>L-index

#	Paper	IF	Citations
691	Mindfulness-based stress reduction for stress management in healthy people: a review and meta-analysis. <i>Journal of Alternative and Complementary Medicine</i> , <b>2009</b> , 15, 593-600	2.4	940
690	Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. <i>Clinical Psychology Review</i> , <b>2011</b> , 31, 449-64	10.8	720
689	Genome-wide association study identifies 30 loci associated with bipolar disorder. <i>Nature Genetics</i> , <b>2019</b> , 51, 793-803	36.3	662
688	The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 1249-62	11.9	451
687	A systematic review of neurobiological and clinical features of mindfulness meditations. <i>Psychological Medicine</i> , <b>2010</b> , 40, 1239-52	6.9	440
686	Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. <i>Psychiatry Research</i> , <b>2011</b> , 187, 441-53	9.9	436
685	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. <i>Molecular Psychiatry</i> , <b>2007</b> , 12, 247-57	15.1	427
684	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. <i>Cell</i> , <b>2019</b> , 179, 1469-1482.e11	56.2	402
683	Antidepressants and body weight: a comprehensive review and meta-analysis. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1259-72	4.6	356
682	Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. <i>Molecular Psychiatry</i> , <b>2010</b> , 15, 473-500	15.1	354
681	Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 259-66	1.7	353
680	Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 1062-70	4.6	313
679	The role of specific early trauma in adult depression: A meta-analysis of published literature. Childhood trauma and adult depression. <i>European Psychiatry</i> , <b>2015</b> , 30, 665-80	6	252
678	Mindfulness: top-down or bottom-up emotion regulation strategy?. <i>Clinical Psychology Review</i> , <b>2013</b> , 33, 82-96	10.8	247
677	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 239-58	1.2	238
676	Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. <i>American Journal of Medical Genetics Part A</i> , <b>2003</b> , 123B, 23-6		233
675	Mindfulness-based interventions for chronic pain: a systematic review of the evidence. <i>Journal of Alternative and Complementary Medicine</i> , <b>2011</b> , 17, 83-93	2.4	220

# (2013-2014)

674	Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. <i>Substance Use and Misuse</i> , <b>2014</b> , 49, 492-512	2.2	214
673	Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. <i>Biological Psychiatry</i> , <b>2001</b> , 50, 323-30	7.9	197
672	Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. <i>Molecular Psychiatry</i> , <b>2018</b> , 23, 133-142	15.1	188
671	Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. <i>American Journal of Medical Genetics Part A</i> , <b>2003</b> , 121B, 35-8		184
670	Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. <i>Journal of Clinical Psychiatry</i> , <b>2000</b> , 61, 26-9	4.6	180
669	Serotonin transporter gene variants and behavior: a comprehensive review. <i>Current Drug Targets</i> , <b>2006</b> , 7, 1659-69	3	169
668	A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. <i>Neuroscience Letters</i> , <b>2004</b> , 368, 123-6	3.3	168
667	Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. <i>Neuroscience Letters</i> , <b>2005</b> , 376, 51-5	3.3	164
666	Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. <i>Molecular Psychiatry</i> , <b>2001</b> , 6, 586-92	15.1	153
665	Depressive symptomatology is influenced by chronotypes. <i>Journal of Affective Disorders</i> , <b>2009</b> , 119, 10	0 <b>-6</b> .6	152
665	Depressive symptomatology is influenced by chronotypes. <i>Journal of Affective Disorders</i> , <b>2009</b> , 119, 10.  The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. <i>Molecular Psychiatry</i> , <b>2008</b> , 13, 742-71	15.1	152 151
	The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future		
664	The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. <i>Molecular Psychiatry</i> , <b>2008</b> , 13, 742-71  Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric</i>	15.1	151
664	The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. <i>Molecular Psychiatry</i> , <b>2008</b> , 13, 742-71  Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 631-5  Pharmacogenetics in major depression: a comprehensive meta-analysis. <i>Progress in</i>	15.1 3.5	151 149
<ul><li>664</li><li>663</li><li>662</li></ul>	The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. <i>Molecular Psychiatry</i> , <b>2008</b> , 13, 742-71  Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 631-5  Pharmacogenetics in major depression: a comprehensive meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 45, 183-94  A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences	3.5 5.5	151 149 148
<ul><li>664</li><li>663</li><li>662</li><li>661</li></ul>	The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. <i>Molecular Psychiatry</i> , <b>2008</b> , 13, 742-71  Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 631-5  Pharmacogenetics in major depression: a comprehensive meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 45, 183-94  A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. <i>Neuroscience Letters</i> , <b>2004</b> , 355, 37-40  Variability of 5-HT2C receptor cys23ser polymorphism among European populations and	3.5 5.5 3.3	151 149 148
<ul><li>664</li><li>663</li><li>662</li><li>661</li><li>660</li></ul>	The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. <i>Molecular Psychiatry</i> , <b>2008</b> , 13, 742-71  Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 631-5  Pharmacogenetics in major depression: a comprehensive meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 45, 183-94  A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. <i>Neuroscience Letters</i> , <b>2004</b> , 355, 37-40  Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. <i>Molecular Psychiatry</i> , <b>2001</b> , 6, 579-85  Personality and attempted suicide. Analysis of anger, aggression and impulsivity. <i>Journal of</i>	3.5 5.5 3.3 15.1	151 149 148 143

656	HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. <i>Current Medicinal Chemistry</i> , <b>2007</b> , 14, 2053-69	4.3	119
655	Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. <i>Molecular Psychiatry</i> , <b>2005</b> , 10, 598-605	15.1	119
654	Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2005</b> , 137B, 36-9	3.5	117
653	Serum concentrations of CRP, IL-6, TNF-hand cortisol in major depressive disorder with melancholic or atypical features. <i>Psychiatry Research</i> , <b>2012</b> , 198, 74-80	9.9	113
652	Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. <i>American Journal of Psychiatry</i> , <b>1999</b> , 156, 1450-2	11.9	113
651	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. <i>Journal of Psychiatric Research</i> , <b>2011</b> , 45, 309-21	5.2	112
650	Pharmacogenetics of antidepressant response. <i>Journal of Psychiatry and Neuroscience</i> , <b>2011</b> , 36, 87-113	4.5	112
649	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 398-404	5.5	112
648	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 617-29	11.9	111
647	The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. <i>International Journal of Neuropsychopharmacology</i> , <b>2004</b> , 7, 453-60	5.8	109
646	A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. <i>International Clinical Psychopharmacology</i> , <b>2011</b> , 26, 130-40	2.2	106
645	Serotonin transporter gene associated with lithium prophylaxis in mood disorders. <i>Pharmacogenomics Journal</i> , <b>2001</b> , 1, 71-7	3.5	103
644	Clozapine resistance: augmentation strategies. European Neuropsychopharmacology, <b>2012</b> , 22, 165-82	1.2	99
643	Social brain, social dysfunction and social withdrawal. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2019</b> , 97, 10-33	9	96
642	Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. <i>International Journal of Neuropsychopharmacology</i> , <b>2007</b> , 10, 437-47	5.8	94
641	Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. <i>Psychiatry Research</i> , <b>2016</b> , 240, 421-430	9.9	94
640	The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2005</b> , 29, 1074-84	5.5	92
639	Serotonergic genes and suicide: a systematic review. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 112	2 <del>5.</del> <b>4</b> 2	91

638	European Group for the Study of Resistant Depression (GSRD)where have we gone so far: review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 453-68	1.2	91
637	Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. <i>Psychiatric Genetics</i> , <b>2003</b> , 13, 179-81	2.9	90
636	Serotonin transporter gene (5-HTTLPR) is not associated with depressive symptomatology in mood disorders. <i>Molecular Psychiatry</i> , <b>1999</b> , 4, 280-3	15.1	89
635	Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. <i>European Neuropsychopharmacology</i> , <b>2001</b> , 11, 375-80	1.2	88
634	New antipsychotics and schizophrenia: a review on efficacy and side effects. <i>Current Medicinal Chemistry</i> , <b>2004</b> , 11, 343-58	4.3	87
633	Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. <i>Journal of Affective Disorders</i> , <b>2006</b> , 90, 251-6	6.6	86
632	Paroxetine for the treatment of depression: a critical update. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 421-31	4	84
631	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. <i>Nature Genetics</i> , <b>2021</b> , 53, 817-829	36.3	83
630	SSRIs antidepressant activity is influenced by G beta 3 variants. <i>European Neuropsychopharmacology</i> , <b>2003</b> , 13, 117-22	1.2	82
629	Weight gain in antipsychotic-naive patients: a review and meta-analysis. <i>Psychological Medicine</i> , <b>2010</b> , 40, 187-200	6.9	81
628	Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients. <i>Psychiatry Research</i> , <b>2012</b> , 200, 389-94	9.9	79
627	Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2009</b> , 150B, 115-23	3.5	79
626	Genetics of Alzheimer's disease. A rapidly evolving field. <i>Journal of Alzheimer</i> Disease, <b>2007</b> , 12, 73-92	4.3	79
625	Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. <i>International Journal of Neuropsychopharmacology</i> , <b>2002</b> , 5, 27-35	5.8	78
624	Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. <i>Journal of Psychiatric Research</i> , <b>1999</b> , 33, 371-7	5.2	77
623	The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2013</b> , 263, 105-18	5.1	76
622	Serotonin transporter gene (5-HTTLPR) and major psychoses. <i>Molecular Psychiatry</i> , <b>2002</b> , 7, 95-9	15.1	76
621	The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2013</b> , 37, 1597-610	9	75

620	Profiles of "manic" symptoms in bipolar I, bipolar II and major depressive disorders. <i>Journal of Affective Disorders</i> , <b>2005</b> , 84, 159-66	6.6	75
619	The 5-HTTLPR polymorphism and posttraumatic stress disorder: a meta-analysis. <i>Journal of Traumatic Stress</i> , <b>2013</b> , 26, 645-53	3.8	74
618	Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. <i>European Journal of Human Genetics</i> , <b>2004</b> , 12, 377-82	5.3	73
617	Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. <i>Biological Psychiatry</i> , <b>2003</b> , 54, 687-92	7.9	73
616	Switching antidepressant class does not improve response or remission in treatment-resistant depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2011</b> , 31, 512-6	1.7	71
615	Pharmacogenetic studies in depression: a proposal for methodologic guidelines. <i>Pharmacogenomics Journal</i> , <b>2008</b> , 8, 90-100	3.5	70
614	Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2005</b> , 19, 97-105	2.6	70
613	Psychological mechanisms of mindfulness-based interventions: what do we know?. <i>Holistic Nursing Practice</i> , <b>2014</b> , 28, 124-48	1.2	69
612	Social adjustment and self-esteem of bipolar patients: a multicentric study. <i>Journal of Affective Disorders</i> , <b>2004</b> , 79, 97-103	6.6	68
611	Psychometric characteristic of the Italian version of the Temperament and Character Inventoryrevised, personality, psychopathology, and attachment styles. <i>Comprehensive Psychiatry</i> , <b>2008</b> , 49, 514-22	7:3	67
610	Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2013</b> , 162B, 487-520	3.5	66
609	HTR2C and HTR1A gene variants in German and Italian suicide attempters and completers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 291-9	3.5	66
608	Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. <i>Journal of Affective Disorders</i> , <b>2009</b> , 115, 27-35	6.6	64
607	Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms. <i>Neuropsychobiology</i> , <b>2006</b> , 53, 9-16	4	64
606	Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. <i>Psychiatry Research</i> , <b>2003</b> , 119, 99-111	9.9	64
605	Pharmacogenetics in the treatment of depression: pharmacodynamic studies. <i>Pharmacogenetics and Genomics</i> , <b>2005</b> , 15, 61-7	1.9	64
604	Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. <i>Journal of Affective Disorders</i> , <b>2013</b> , 147, 1-8	6.6	63
603	Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. <i>Journal of Psychiatric Research</i> , <b>2000</b> , 34, 89-98	5.2	63

#### (2015-2018)

602	The association between electrodermal activity (EDA), depression and suicidal behaviour: A systematic review and narrative synthesis. <i>BMC Psychiatry</i> , <b>2018</b> , 18, 22	4.2	62	
601	Sexual side effects of pharmacological treatment of psychiatric diseases. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 142-7	6.1	62	
600	Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. <i>Psychiatry Research</i> , <b>1999</b> , 87, 7-19	9.9	62	
599	The 5-HTTLPR polymorphism and eating disorders: a meta-analysis. <i>International Journal of Eating Disorders</i> , <b>2011</b> , 44, 191-9	6.3	61	
598	Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. <i>American Journal of Medical Genetics Part A</i> , <b>2004</b> , 129B, 36-40		61	
597	Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. <i>Biological Psychiatry</i> , <b>2001</b> , 49, 405-9	7.9	61	
596	Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. <i>Drug and Alcohol Dependence</i> , <b>1994</b> , 36, 139-45	4.9	60	
595	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 1101-15	5.5	59	
594	Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. <i>Biomedicine and Pharmacotherapy</i> , <b>2009</b> , 63, 228-35	7.5	59	
593	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 441-53	1.2	58	
592	Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample. <i>Journal of Clinical Psychiatry</i> , <b>2018</b> , 79,	4.6	58	
591	Genetic modulation of personality traits: a systematic review of the literature. <i>International Clinical Psychopharmacology</i> , <b>2014</b> , 29, 1-15	2.2	57	
590	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. <i>International Clinical Psychopharmacology</i> , <b>2009</b> , 24, 250-6	2.2	57	
589	The pharmacogenomics of selective serotonin reuptake inhibitors. <i>Pharmacogenomics Journal</i> , <b>2004</b> , 4, 233-44	3.5	57	
588	Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders. <i>American Journal of Medical Genetics Part A</i> , <b>2002</b> , 114, 361-9		57	
587	Temperament and character of suicide attempters. <i>Journal of Psychiatric Research</i> , <b>2008</b> , 42, 938-45	5.2	56	
586	Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. <i>CNS Drugs</i> , <b>2008</b> , 22, 367-88	6.7	56	
585	Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. <i>Current Psychiatry Reports</i> , <b>2015</b> , 17, 50	9.1	55	

584	Pharmacogenetics of antidepressants. Frontiers in Pharmacology, <b>2011</b> , 2, 6	5.6	55
583	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , <b>2016</b> , 189, 224-32	6.6	54
582	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. <i>World Journal of Biological Psychiatry</i> , <b>2017</b> , 18, 5-28	3.8	54
581	The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. <i>Progress in Neurobiology</i> , <b>2011</b> , 94, 418-60	10.9	54
580	DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. <i>American Journal of Medical Genetics Part A</i> , <b>2001</b> , 105, 283-90		54
579	The influence of childhood trauma on the onset and repetition of suicidal behavior: an investigation in a high risk sample of male prisoners. <i>Journal of Psychiatric Research</i> , <b>2011</b> , 45, 742-7	5.2	53
578	The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. <i>International Clinical Psychopharmacology</i> , <b>2008</b> , 23, 1-8	2.2	53
577	Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. <i>Molecular Psychiatry</i> , <b>2000</b> , 5, 270-4	15.1	53
576	Mode of inheritance in mood disorder families according to fluvoxamine response. <i>Acta Psychiatrica Scandinavica</i> , <b>1998</b> , 98, 443-50	6.5	52
575	How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. <i>European Neuropsychopharmacology</i> , <b>2007</b> , 17, 587-94	1.2	52
574	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , <b>2019</b> , 139, 78-88	6.5	52
573	Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , <b>2019</b> , 20, 427-448	3.8	51
572	Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. <i>Human Heredity</i> , <b>1997</b> , 47, 6-16	1.1	51
571	Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. <i>Pharmacogenomics Journal</i> , <b>2004</b> , 4, 267-73	3.5	51
570	Symptomatologic analysis of psychotic and non-psychotic depression. <i>Journal of Affective Disorders</i> , <b>1999</b> , 54, 183-7	6.6	51
569	Identification of symptomatologic patterns common to major psychoses: proposal for a phenotype definition. <i>American Journal of Medical Genetics Part A</i> , <b>1996</b> , 67, 393-400		51
568	No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. <i>Psychiatry Research</i> , <b>2001</b> , 104, 195-203	9.9	49
567	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , <b>2017</b> , 78, 215-222	4.6	49

#### (2008-2002)

566	Excess of allele1 for alpha3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. <i>Molecular Psychiatry</i> , <b>2002</b> , 7, 201-7	15.1	48	
565	Clinical and demographic features of mood disorder subtypes. <i>Psychiatry Research</i> , <b>2002</b> , 112, 195-210	9.9	48	
564	5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. <i>International Journal of Neuropsychopharmacology</i> , <b>2008</b> , 11, 701-21	5.8	47	
563	Tryptophan hydroxylase gene and major psychoses. <i>Psychiatry Research</i> , <b>2001</b> , 103, 79-86	9.9	47	
562	A quantitative approach to neuropsychiatry: The why and the how. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2019</b> , 97, 3-9	9	47	
561	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 91, 1-13	5.2	46	
560	Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. <i>Neuropsychobiology</i> , <b>2012</b> , 65, 1-11	4	46	
559	Mindfulness-based cognitive therapy versus psycho-education for patients with major depression who did not achieve remission following antidepressant treatment: a preliminary analysis. <i>Journal of Alternative and Complementary Medicine</i> , <b>2012</b> , 18, 756-60	2.4	46	
558	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders. <i>American Journal of Medical Genetics Part A</i> , <b>2002</b> , 114, 177-185		46	
557	Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. <i>American Journal of Medical Genetics Part A</i> , <b>2002</b> , 114, 370-9		46	
556	Dimensions of major psychoses: a confirmatory factor analysis of six competing models. <i>Psychiatry Research</i> , <b>2004</b> , 127, 101-9	9.9	46	
555	Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. <i>Psychiatric Genetics</i> , <b>2006</b> , 16, 153-8	2.9	45	
554	Depressive syndrome in major psychoses: a study on 1351 subjects. <i>Psychiatry Research</i> , <b>2004</b> , 127, 85-9	<b>9</b> 9.9	45	
553	Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. <i>Psychiatry Research</i> , <b>2015</b> , 226, 474-83	9.9	44	
552	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 971-985	1.2	44	
551	Antidepressants in healthy subjects: what are the psychotropic/psychological effects?. <i>European Neuropsychopharmacology</i> , <b>2010</b> , 20, 433-53	1.2	44	
550	Focus on HTR2C: A possible suggestion for genetic studies of complex disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2009</b> , 150B, 601-37	3.5	44	
549	NOS-I and -III gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2008</b> , 147B, 42-8	3.5	44	

548	Pharmacogenetics in affective disorders. European Journal of Pharmacology, 2002, 438, 117-28	5.3	44
547	Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. <i>Journal of Psychiatry and Neuroscience</i> , <b>2015</b> , 40, 174-86	4.5	43
546	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. <i>Journal of Affective Disorders</i> , <b>2011</b> , 128, 56-63	6.6	43
545	Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 1561-70	4	43
544	The 5-HT2C receptor as a target for mood disorders. Expert Opinion on Therapeutic Targets, 2004, 8, 15	-2 <b>6</b> .4	43
543	Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. <i>American Journal of Medical Genetics Part A</i> , <b>2002</b> , 114, 380-90		43
542	The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2018</b> , 16, 1-6	3.4	43
541	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 76-92	11.9	43
540	Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression. <i>Journal of Affective Disorders</i> , <b>1999</b> , 56, 17-25	6.6	42
539	Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. <i>International Journal of Neuropsychopharmacology</i> , <b>2004</b> , 7, 489-93	5.8	41
538	Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. <i>Psychopharmacology</i> , <b>2013</b> , 227, 509-19	4.7	40
537	Cognitive markers of psychotic unipolar depression: a meta-analytic study. <i>Journal of Affective Disorders</i> , <b>2015</b> , 174, 580-8	6.6	40
536	Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. <i>Clinical Neuropharmacology</i> , <b>2011</b> , 34, 39-47	1.4	40
535	Interaction between SERTPR and stressful life events on response to antidepressant treatment. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 64-7	1.2	40
534	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 562-70	1.2	40
533	Tyrosine hydroxylase gene associated with depressive symptomatology in mood disorder <b>1998</b> , 81, 12	7-130	40
532	From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. <i>Psychopharmacology</i> , <b>2004</b> , 174, 490-503	4.7	40
531	Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. <i>International Journal of Neuropsychopharmacology</i> , <b>1998</b> , 1, 125-129	5.8	40

530	European Collaborative Project on Affective Disorders: interactions between genetic and psychosocial vulnerability factors. <i>Psychiatric Genetics</i> , <b>1998</b> , 8, 197-205	2.9	40	
529	Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 64, 88-98	5.2	39	
528	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. <i>International Clinical Psychopharmacology</i> , <b>2009</b> , 24, 1-18	2.2	39	
527	Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 1562-6	5.5	39	
526	Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. <i>Psychiatry Research</i> , <b>2007</b> , 149, 185-93	9.9	39	
525	Shared genetics among major psychiatric disorders. <i>Lancet, The</i> , <b>2013</b> , 381, 1339-1341	40	38	
524	Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. <i>Psychiatry Research</i> , <b>2011</b> , 189, 26-32	9.9	38	
523	Dopamine receptor D2 Ser/Cys311 variant associated with disorganized symptomatology of schizophrenia. <i>Schizophrenia Research</i> , <b>1998</b> , 34, 207-10	3.6	38	
522	Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 163-185	1.2	37	
521	5-HTTLPR and gender differences in affective disorders: A systematic review. <i>Journal of Affective Disorders</i> , <b>2016</b> , 190, 193-207	6.6	37	
520	From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. <i>Canadian Journal of Psychiatry</i> , <b>2014</b> , 59, 62-75	4.8	37	
519	Clinical, psychological and environmental predictors of prospective suicide events in patients with Bipolar Disorder. <i>Journal of Psychiatric Research</i> , <b>2013</b> , 47, 1800-8	5.2	37	
518	Newer antidepressants and panic disorder: a meta-analysis. <i>International Clinical Psychopharmacology</i> , <b>2013</b> , 28, 33-45	2.2	37	
517	Quetiapine XR: current status for the treatment of major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2010</b> , 34, 1165-73	5.5	37	
516	Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders. <i>Psychiatry Research</i> , <b>2008</b> , 158, 132-40	9.9	37	
515	Neural network analysis in pharmacogenetics of mood disorders. <i>BMC Medical Genetics</i> , <b>2004</b> , 5, 27	2.1	37	
514	Influence of 5-HTTLPR and TPH variants on illness time course in mood disorders. <i>Journal of Psychiatric Research</i> , <b>2001</b> , 35, 217-23	5.2	37	
513	Genetic modulation of borderline personality disorder: systematic review and meta-analysis. Journal of Psychiatric Research, 2013, 47, 1275-87	5.2	36	

512	Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. <i>International Journal of Alzheimers Disease</i> , <b>2011</b> , 2011, 832379	3.7	36
511	A protective genetic variant for adverse environments? The role of childhood traumas and serotonin transporter gene on resilience and depressive severity in a high-risk population. <i>European Psychiatry</i> , <b>2011</b> , 26, 471-8	6	36
510	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. <i>Journal of Psychiatric Research</i> , <b>2009</b> , 43, 519-25	5.2	36
509	Quetiapine for bipolar depression: a systematic review and meta-analysis. <i>International Clinical Psychopharmacology</i> , <b>2012</b> , 27, 76-90	2.2	36
508	Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 809-15	3.5	36
507	Serotonin transporter gene and adverse life events in adult ADHD. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2008</b> , 147B, 1461-9	3.5	36
506	Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. <i>Depression and Anxiety</i> , <b>2006</b> , 23, 389-97	8.4	36
505	Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. <i>Psychopharmacology</i> , <b>2004</b> , 174, 504-11	4.7	36
504	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. <i>International Clinical Psychopharmacology</i> , <b>1996</b> , 11, 109-17	2.2	36
503	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2013</b> , 44, 271-8	5.5	35
502	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder <b>2000</b> , 96, 136-140		35
501	A meta-analysis of cognitive performance in melancholic versus non-melancholic unipolar depression. <i>Journal of Affective Disorders</i> , <b>2016</b> , 201, 15-24	6.6	35
500	Escitalopram plasma levels and antidepressant response. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 940-944	1.2	34
499	Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 296-3	s <del>0</del> 37	34
498	Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. <i>World Journal of Biological Psychiatry</i> , <b>2011</b> , 12, 364-75	3.8	34
497	Dopamine receptor D4 gene is associated with delusional symptomatology in mood disorders. <i>Psychiatry Research</i> , <b>1998</b> , 80, 129-36	9.9	34
496	Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2001</b> , 251, 193-8	5.1	34
495	Factor analysis of delusional disorder symptomatology. <i>Comprehensive Psychiatry</i> , <b>1999</b> , 40, 143-7	7.3	34

# (2004-2017)

494	Genetics of schizophrenia: A consensus paper of the WFSBP Task Force on Genetics. <i>World Journal of Biological Psychiatry</i> , <b>2017</b> , 18, 492-505	3.8	33	
493	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 1960-1971	1.2	33	
492	The CLOCK gene and mood disorders: a case-control study and meta-analysis. <i>Chronobiology International</i> , <b>2011</b> , 28, 825-33	3.6	33	
491	Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2008</b> , 258, 239-44	5.1	33	
490	Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. <i>Psychiatry Research</i> , <b>2004</b> , 125, 65-8	9.9	33	
489	Factor analysis of mania. Archives of General Psychiatry, 1999, 56, 671-2		33	
488	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 539-549	5.8	32	
487	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disordera European multicenter study. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 259-66	1.2	32	
486	Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients. <i>Journal of Affective Disorders</i> , <b>2009</b> , 119, 205-9	6.6	32	
485	Genetic variants of dopamine receptor D4 and psychopathology. Schizophrenia Bulletin, 1999, 25, 609-	181.3	32	
484	Social adjustment and self-esteem in remitted patients with mood disorders. <i>European Psychiatry</i> , <b>1999</b> , 14, 137-42	6	32	
483	A Glutamate Transporter EAAT1 Gene Variant Influences Amygdala Functional Connectivity in Bipolar Disorder. <i>Journal of Molecular Neuroscience</i> , <b>2018</b> , 65, 536-545	3.3	31	
482	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 463-72	3.5	31	
481	Functional neural correlates of mindfulness meditations in comparison with psychotherapy, pharmacotherapy and placebo effect. Is there a link?. <i>Acta Neuropsychiatrica</i> , <b>2010</b> , 22, 104-17	3.9	31	
480	Heat-shock protein-70 genes and response to antidepressants in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2007</b> , 31, 1006-11	5.5	31	
479	5-HT2A SNPs and the Temperament and Character Inventory. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2007</b> , 31, 1275-81	5.5	31	
478	Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. <i>Neuroscience Research</i> , <b>2005</b> , 53, 8-13	2.9	31	
477	Banl polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. <i>Neuropsychobiology</i> , <b>2004</b> , 49, 185-8	4	31	

476	White Matter Microstructure in Bipolar Disorder Is Influenced by the Interaction between a Glutamate Transporter EAAT1 Gene Variant and Early Stress. <i>Molecular Neurobiology</i> , <b>2019</b> , 56, 702-710	0 <sup>6.2</sup>	30
475	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , <b>2015</b> , 184, 51-9	6.6	30
474	Mechanisms of antidepressant action: an integrated dopaminergic perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 1532-43	5.5	30
473	3111T/C clock gene polymorphism is not associated with sleep disturbances in untreated depressed patients. <i>Chronobiology International</i> , <b>2010</b> , 27, 265-77	3.6	30
472	Pharmacogenetics of antidepressant response: an update. <i>Human Genomics</i> , <b>2009</b> , 3, 257-74	6.8	30
471	Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2018</b> , 86, 36-44	5.5	30
470	Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. <i>Journal of Affective Disorders</i> , <b>2015</b> , 179, 88-94	6.6	29
469	Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2012</b> , 262, 199-205	5.1	29
468	A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. <i>World Journal of Biological Psychiatry</i> , <b>2011</b> , 12, 501-15	3.8	29
467	The use of the defence style questionnaire in major depressive and panic disorders: a comprehensive meta-analysis. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , <b>2010</b> , 83, 1-13	3.5	29
466	Analysis of depressive symptomatology in mood disorders. <i>Depression and Anxiety</i> , <b>1998</b> , 8, 80-85	8.4	29
465	Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 1041-4	5.5	29
464	Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. <i>Psychiatry Research</i> , <b>2006</b> , 145, 61-5	9.9	29
463	Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. <i>Psychiatry and Clinical Neurosciences</i> , <b>2006</b> , 60, 598-	-60 <del>2</del>	29
462	Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. <i>Psychiatry Research</i> , <b>2004</b> , 127, 279-81	9.9	29
461	Genes involved in Alzheimer's disease, a survey of possible candidates. <i>Journal of Alzheimerg Disease</i> , <b>2005</b> , 7, 331-53	4.3	29
460	Clinical and demographic features of psychotic and nonpsychotic depression. <i>Comprehensive Psychiatry</i> , <b>1999</b> , 40, 358-62	7.3	29
459	Depression across mood disorders: review and analysis in a clinical sample. <i>Comprehensive Psychiatry</i> , <b>2012</b> , 53, 24-38	7.3	28

# (2003-2010)

458	MDR1 gene polymorphisms and response to acute risperidone treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2010</b> , 34, 387-92	5.5	28	
457	Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 701-3	3.5	28	
456	No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. <i>Neuropsychobiology</i> , <b>2007</b> , 56, 167-71	4	28	
455	Catechol-O-methyltransferase gene variants in mood disorders in the Italian population. <i>Psychiatric Genetics</i> , <b>2006</b> , 16, 181-2	2.9	28	
454	Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 607-13		28	
453	Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , <b>2004</b> , 14, 147-50	2.9	28	
452	Serotonin transporter gene is not associated with symptomatology of schizophrenia. <i>Schizophrenia Research</i> , <b>1999</b> , 35, 33-9	3.6	28	
451	Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2012</b> , 36, 147-54	5.5	27	
450	The role of serotonergic genes and environmental stress on the development of depressive symptoms and neuroticism. <i>Journal of Affective Disorders</i> , <b>2012</b> , 142, 82-9	6.6	27	
449	COMT and age at onset in mood disorders: a replication and extension study. <i>Neuroscience Letters</i> , <b>2011</b> , 498, 218-21	3.3	27	
448	Vitamin B12 levels in Alzheimer's disease: association with clinical features and cytokine production. <i>Journal of Alzheimer&amp; Disease</i> , <b>2010</b> , 19, 481-8	4.3	27	
447	HTR2C (cys23ser) polymorphism influences early onset in bipolar patients in a large European multicenter association study. <i>Molecular Psychiatry</i> , <b>2007</b> , 12, 797-8	15.1	27	
446	Genetics of long-term treatment outcome in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2016</b> , 65, 17-24	5.5	26	
445	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behaviors: a meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 88, 375-387	5.5	26	
444	Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. <i>Journal of Neural Transmission</i> , <b>2013</b> , 120, 1709-15	4.3	26	
443	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 887-94	1.2	26	
442	HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 5-27	2.8	26	
441	Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , <b>2003</b> , 57, 399-403	6.2	26	

440	Patterns of symptom improvement during antidepressant treatment of delusional depression. <i>Psychiatry Research</i> , <b>2000</b> , 94, 185-90	9.9	26
439	Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation. <i>Psychiatry Research</i> , <b>1999</b> , 89, 107-14	9.9	26
438	Genetics of resilience: Implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2020</b> , 183, 77-94	3.5	26
437	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , <b>2015</b> , 15, 538-48	3.5	25
436	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 137, 401-412	6.5	25
435	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 752	2-760	25
434	Clinical and genetic factors associated with suicide in mood disorder patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2016</b> , 266, 181-93	5.1	25
433	Schizophrenia-like symptoms in narcolepsy type 1: shared and distinctive clinical characteristics. <i>Neuropsychobiology</i> , <b>2015</b> , 71, 218-24	4	25
432	TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. <i>Neuropsychobiology</i> , <b>2013</b> , 67, 41-7	4	25
431	Components of self-esteem in affective patients and non-psychiatric controls. <i>Journal of Affective Disorders</i> , <b>2005</b> , 88, 93-8	6.6	25
430	Neuroticism, social network, stressful life events: association with mood disorders, depressive symptoms and suicidal ideation in a community sample of women. <i>Psychiatry Research</i> , <b>2015</b> , 226, 38-44	9.9	24
429	Family history of a mood disorder indicates a more severe bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2014</b> , 156, 178-86	6.6	24
428	Clinical features and drug induced side effects in early versus late antidepressant responders. Journal of Psychiatric Research, <b>2013</b> , 47, 1309-18	5.2	24
427	Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. <i>Pharmacogenetics and Genomics</i> , <b>2014</b> , 24, 314-9	1.9	24
426	The 3111T/C polymorphism interacts with stressful life events to influence patterns of sleep in females. <i>Chronobiology International</i> , <b>2012</b> , 29, 891-7	3.6	24
425	APOE epsilon-4 allele and cytokine production in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , <b>2010</b> , 25, 338-44	3.9	24
424	Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. <i>Psychiatric Genetics</i> , <b>2003</b> , 13, 121-6	2.9	24
423	Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 751-7	5.5	24

#### (2013-2005)

422	Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2005</b> , 25, 471-5	1.7	24	
421	5-HT 1A polymorphism and self-transcendence in mood disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2005</b> , 137B, 33-5	3.5	24	
420	Linkage of mood disorders with D2, D3 and TH genes: a multicenter study. <i>Journal of Affective Disorders</i> , <b>2000</b> , 58, 51-61	6.6	24	
419	Impact of clinical variables on illness time course in mood disorders. <i>Psychiatry Research</i> , <b>2000</b> , 97, 217-	<b>23</b> .9	24	
418	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , <b>2019</b> , 214, 36-41	5.4	24	
417	Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 263-75	1.2	23	
416	Specificity profile of venlafaxine and sertraline in major depression: metaregression of double-blind, randomized clinical trials. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 1-8	5.8	23	
415	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2012</b> , 262, 305-11	5.1	23	
414	Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta). <i>Current Medicinal Chemistry</i> , <b>2009</b> , 16, 1917-48	4.3	23	
413	5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. <i>Psychiatry Research</i> , <b>2009</b> , 167, 97-105	9.9	23	
412	Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 69-75	1.9	23	
411	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 575540	5.6	23	
410	Predictors of switch from depression to mania in bipolar disorder. <i>Journal of Psychiatric Research</i> , <b>2015</b> , 66-67, 45-53	5.2	22	
409	Progress and prospects in pharmacogenetics of antidepressant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1157-68	5.5	22	
408	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , <b>2016</b> , 204, 54-8	6.6	22	
407	Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis. <i>Molecular Neurobiology</i> , <b>2016</b> , 53, 2065-2081	6.2	22	
406	MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2013</b> , 263, 393-403	5.1	22	
405	Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 612-21	1.2	22	

404	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2017</b> , 174, 757-764	3.5	22
403	Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials. <i>Journal of Affective Disorders</i> , <b>2011</b> , 132, 14-25	6.6	22
402	T3111C clock single nucleotide polymorphism and mood disorders: a meta-analysis. <i>Chronobiology International</i> , <b>2010</b> , 27, 706-21	3.6	22
401	Lack of association between interleukin-1 alpha rs1800587 polymorphism and Alzheimer's disease in two Independent European samples. <i>Journal of Alzheimer&amp; Disease</i> , <b>2009</b> , 16, 181-7	4.3	22
400	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. Journal of Psychiatric Research, <b>2010</b> , 44, 598-604	5.2	22
399	Clinical prediction of antidepressant response in mood disorders: linear multivariate vs. neural network models. <i>Psychiatry Research</i> , <b>2007</b> , 152, 223-31	9.9	22
398	Dopamine transporter haplotype and attention-deficit hyperactivity disorder. <i>Molecular Psychiatry</i> , <b>2005</b> , 10, 617-8	15.1	22
397	Genetics of serotonin receptors and depression: state of the art. Current Drug Targets, 2013, 14, 531-48	3	22
396	Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naWe patients with first major depression episode. <i>Journal of Psychiatric Research</i> , <b>2013</b> , 47, 162-7	5.2	21
395	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , <b>2012</b> , 516, 85-8	3.3	21
394	Phenomenology of psychotic mood disorders: lifetime and major depressive episode features. Journal of Affective Disorders, <b>2011</b> , 135, 241-50	6.6	21
393	Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2012</b> , 11, 299-305	2.6	21
392	The socio-economical burden of schizophrenia: a simulation of cost-offset of early intervention program in Italy. <i>European Psychiatry</i> , <b>2009</b> , 24, 11-6	6	21
391	Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 121-8	1.9	21
390	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. <i>Journal of Psychiatric Research</i> , <b>2010</b> , 44, 487-92	5.2	21
389	The serotonin transporter gene and effectiveness of SSRIs. <i>Expert Review of Neurotherapeutics</i> , <b>2008</b> , 8, 111-20	4.3	21
388	Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. <i>Psychiatry Research</i> , <b>2003</b> , 118, 241-7	9.9	21
387	Predicting response to lithium in mood disorders: role of genetic polymorphisms. <i>Molecular Diagnosis and Therapy</i> , <b>2003</b> , 3, 17-30		21

386	Dopamine receptor D4 gene is not associated with major psychoses <b>1999</b> , 88, 486-491		21
385	Serotonin transporter gene not associated with psychotic symptomatology of mood disorders. <i>Psychiatry Research</i> , <b>1999</b> , 86, 59-65	9.9	21
384	Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 206-16	1.9	21
383	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2018</b> , 81, 203-210	5.5	20
382	The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. Journal of Psychiatric Research, <b>2014</b> , 56, 72-81	5.2	20
381	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2013</b> , 263, 93-103	5.1	20
380	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 895-901	1.2	20
379	Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. <i>Neuropsychobiology</i> , <b>2012</b> , 65, 70-5	4	20
378	Incomplete coverage of candidate genes: a poorly considered bias. Current Genomics, 2007, 8, 476-83	2.6	20
377	Genetic association between the phospholipase A2 gene and unipolar affective disorder: a multicentre case-control study. <i>Psychiatric Genetics</i> , <b>2003</b> , 13, 211-20	2.9	20
376	Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2003</b> , 27, 519-23	5.5	20
375	GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. <i>Psychiatric Genetics</i> , <b>1998</b> , 8, 251-4	2.9	20
374	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 3363-3373	15.1	20
373	Clinical factors related to schizophrenia relapse. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2016</b> , 20, 54-69	2.4	20
372	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , <b>2018</b> , 227, 777-786	6.6	20
371	CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 689-701	2.6	19
370	Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls. <i>Psychiatry Research</i> , <b>2015</b> , 228, 945-9	9.9	19
369	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 106	4.2	19

368	Case-control association study of 36 single-nucleotide polymorphisms within 10 candidate genes for major depression and bipolar disorder. <i>Psychiatry Research</i> , <b>2013</b> , 209, 121-3	9.9	19
367	CACNA1C gene and schizophrenia: a case-control and pharmacogenetic study. <i>Psychiatric Genetics</i> , <b>2015</b> , 25, 163-7	2.9	19
366	Genetic variability in CYP2E1 and catalase gene among currently and formerly alcohol-dependent male subjects. <i>Alcohol and Alcoholism</i> , <b>2015</b> , 50, 140-5	3.5	19
365	The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2011</b> , 156B, 975-86	3.5	19
364	The impact of heat shock protein 70 gene variations on clinical presentation and outcome in schizophrenic inpatients. <i>Neuropsychobiology</i> , <b>2009</b> , 59, 135-41	4	19
363	Serotonin-2C and serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders. <i>American Journal of Medical Genetics Part A</i> , <b>2000</b> , 96, 161-6		19
362	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. <i>Neuropsychobiology</i> , <b>2016</b> , 73, 35-42	4	18
361	The association of personality trait on treatment outcomes in patients with chronic prostatitis/chronic pelvic pain syndrome: an exploratory study. <i>Journal of Psychosomatic Research</i> , <b>2014</b> , 76, 127-33	4.1	18
360	Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder. <i>Psychiatry Research</i> , <b>2012</b> , 198, 39-46	9.9	18
359	Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. <i>Journal of Affective Disorders</i> , <b>2012</b> , 141, 72-8	6.6	18
358	Dysbindin gene (DTNBP1) and schizophrenia in Korean population. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2009</b> , 259, 137-42	5.1	18
357	Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. <i>BMC Psychiatry</i> , <b>2006</b> , 6, 11	4.2	18
356	Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2003</b> , 23, 535-9	1.7	18
355	Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression. <i>Journal of Clinical Psychiatry</i> , <b>2019</b> , 80,	4.6	18
354	No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. <i>Psychiatry Investigation</i> , <b>2013</b> , 10, 180-9	3.1	18
353	Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2020</b> , 18, 1-9	3.4	18
352	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , <b>2016</b> , 19,	5.8	18
351	Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2016</b> , 266, 703-717	5.1	17

#### (2000-2015)

350	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , <b>2015</b> , 35, 220-7	1.7	17	
349	Trait-aggressiveness and impulsivity: role of psychological resilience and childhood trauma in a sample of male prisoners. <i>Nordic Journal of Psychiatry</i> , <b>2014</b> , 68, 8-17	2.3	17	
348	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 616-28	4.6	17	
347	Role of substance abuse comorbidity and personality on the outcome of depression in bipolar disorder: harm avoidance influences medium-term treatment outcome. <i>Psychopathology</i> , <b>2012</b> , 45, 174	1-8 <sup>4</sup>	17	
346	A neural network model for combining clinical predictors of antidepressant response in mood disorders. <i>Journal of Affective Disorders</i> , <b>2007</b> , 98, 239-45	6.6	17	
345	Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study. <i>European Neuropsychopharmacology</i> , <b>2003</b> , 13, 365-8	1.2	17	
344	Polymorphism of the serotonin transporter gene and symptomatic dimensions of schizophrenia in the Korean population. <i>Neuropsychobiology</i> , <b>2003</b> , 47, 182-6	4	17	
343	Serum testosterone concentration in combat-related chronic posttraumatic stress disorder. <i>Neuropsychobiology</i> , <b>2012</b> , 65, 90-5	4	17	
342	Duloxetine plasma level and antidepressant response. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 92, 127-132	5.5	17	
341	Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison. <i>International Clinical Psychopharmacology</i> , <b>2017</b> , 32, 235-248	2.2	16	
340	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , <b>2020</b> , 10, 50	8.6	16	
339	Pharmacogenetics in Psychiatry. Advances in Pharmacology, 2018, 83, 297-331	5.7	16	
338	Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. <i>International Clinical Psychopharmacology</i> , <b>2017</b> , 32, 309-318	2.2	16	
337	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 718-25	1.2	16	
336	Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 375-9	5.5	16	
335	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 757-61	3.5	16	
334	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia <b>2000</b> , 96, 84-87		16	
333	Effect of reboxetine augmentation in SSRI resistant patients. <i>Human Psychopharmacology</i> , <b>2000</b> , 15, 143-145	2.3	16	

332	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatmenta European multicentre study. <i>International Clinical Psychopharmacology</i> , <b>2016</b> , 31, 1-7	2.2	16
331	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2013</b> , 263, 65-74	5.1	15
330	Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability. Journal of Affective Disorders, <b>2013</b> , 148, 316-22	6.6	15
329	Self-harm in prisoners. CNS Spectrums, <b>2011</b> , 16, 75-81	1.8	15
328	Further evidence supporting the influence of brain-derived neurotrophic factor on the outcome of bipolar depression: independent effect of brain-derived neurotrophic factor and harm avoidance. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 1747-54	4.6	15
327	Neuro-imaging of mindfulness meditations: implications for clinical practice. <i>Epidemiology and Psychiatric Sciences</i> , <b>2011</b> , 20, 205-10	5.1	15
326	Tyrosine hydroxylase gene in linkage disequilibrium with mood disorders. <i>Molecular Psychiatry</i> , <b>1998</b> , 3, 169-74	15.1	15
325	Antidepressant response in the elderly. <i>Psychiatry Research</i> , <b>2007</b> , 152, 37-44	9.9	15
324	TNFB polymorphism may be associated with schizophrenia in the Korean population. <i>Schizophrenia Research</i> , <b>2003</b> , 61, 39-45	3.6	15
323	No interaction of GABAA alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses <b>1999</b> , 88, 44-49		15
322	Tyrosine hydroxylase polymorphism and phenotypic heterogeneity in bipolar affective disorder: a multicenter association study. <i>American Journal of Medical Genetics Part A</i> , <b>1999</b> , 88, 527-32		15
321	A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2018</b> , 16, 469-480	3.4	15
320	Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia. <i>OMICS A Journal of Integrative Biology</i> , <b>2016</b> , 20, 283-9	3.8	15
319	Relating constructs of attention and working memory to social withdrawal in Alzheimer's disease and schizophrenia: issues regarding paradigm selection. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2019</b> , 97, 47-69	9	15
318	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2017</b> , 267, 723-735	5.1	14
317	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 625-632	1.2	14
316	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , <b>2019</b> , 252, 464-474	6.6	14
315	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , <b>2015</b> , 16, 472-82	3.8	14

314	Serotonin transporter gene: a new polymorphism may affect response to antidepressant treatments in major depressive disorder. <i>Molecular Diagnosis and Therapy</i> , <b>2014</b> , 18, 567-77	4.5	14	
313	Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2014</b> , 18, 97-102	2.4	14	
312	Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 354-62	1.9	14	
311	A molecular pathway analysis informs the genetic background at risk for schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2015</b> , 59, 21-30	5.5	14	
310	Serious suicidal behaviors: socio-demographic and clinical features in a multinational, multicenter sample. <i>Nordic Journal of Psychiatry</i> , <b>2014</b> , 68, 44-52	2.3	14	
309	Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to antipsychotic treatment in patients with schizophrenia. <i>Neuroscience Letters</i> , <b>2012</b> , 506, 170-4	3.3	14	
308	TAAR6 variations possibly associated with antidepressant response and suicidal behavior. <i>Psychiatry Research</i> , <b>2010</b> , 180, 20-4	9.9	14	
307	Thyroid hormones affect recovery from depression during antidepressant treatment. <i>Psychiatry and Clinical Neurosciences</i> , <b>2009</b> , 63, 305-13	6.2	14	
306	Association between the estrogen receptor TA polymorphism and Harm avoidance. <i>Neuroscience Letters</i> , <b>2009</b> , 467, 155-8	3.3	14	
305	DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. <i>Neuroscience Letters</i> , <b>2008</b> , 440, 150-4	3.3	14	
304	Influence of postpartum onset on the course of mood disorders. BMC Psychiatry, 2006, 6, 4	4.2	14	
303	No evidence for interaction between 5-HT2A receptor and serotonin transporter genes in schizophrenia. <i>Neuroscience Research</i> , <b>2005</b> , 52, 195-9	2.9	14	
302	Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia. <i>Journal of Neural Transmission</i> , <b>2006</b> , 113, 887-97	4.3	14	
301	Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. <i>Psychiatry and Clinical Neurosciences</i> , <b>2003</b> , 57, 153-9	6.2	14	
300	Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population. <i>Psychiatric Genetics</i> , <b>2004</b> , 14, 65-7	2.9	14	
299	Interaction between the tryptophan hydroxylase gene and the serotonin transporter gene in schizophrenia but not in bipolar or unipolar affective disorders. <i>Neuropsychobiology</i> , <b>2005</b> , 51, 3-9	4	14	
298	Rapid cycling mood disorder: clinical and demographic features. <i>Comprehensive Psychiatry</i> , <b>2002</b> , 43, 336-43	7.3	14	
297	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. <i>American Journal of Medical Genetics Part A</i> , <b>1999</b> , 88, 294-297		14	

296	Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. <i>Neuropsychobiology</i> , <b>2016</b> , 74, 159-168	4	14
295	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , <b>2019</b> , 22, 93-104	5.8	14
294	Is cognitive behavioural therapy an effective complement to antidepressants in adolescents? A meta-analysis. <i>Acta Neuropsychiatrica</i> , <b>2011</b> , 23, 263-271	3.9	13
293	Estrogen receptor gene 1 variants are not associated with suicidal behavior. <i>Psychiatry Research</i> , <b>2008</b> , 160, 1-7	9.9	13
292	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2008</b> , 147, 308-15	3.5	13
291	Two new rare variants in the circadian "clock" gene may influence sleep pattern. <i>Genetics in Medicine</i> , <b>2005</b> , 7, 455-7	8.1	13
290	Melancholic features and response to lithium prophylaxis in mood disorders. <i>Depression and Anxiety</i> , <b>2000</b> , 11, 73-9	8.4	13
289	New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. <i>Medicinal Research Reviews</i> , <b>2020</b> , 40, 1794-1832	14.4	13
288	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 1305-1313	1.2	13
287	Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 777-785	1.2	12
286	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. <i>Translational Psychiatry</i> , <b>2015</b> , 5, e513	8.6	12
285	Association between Sirtuin 1 Gene rs10997870 Polymorphism and Suicide Behaviors in Bipolar Disorder. <i>Neuropsychobiology</i> , <b>2016</b> , 74, 1-7	4	12
284	Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 1093-118	5.5	12
283	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2013</b> , 263, 385-91	5.1	12
282	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. <i>International Clinical Psychopharmacology</i> , <b>2010</b> , 25, 297-3	30 <sup>2</sup> 1.2	12
281	TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: an open label study. <i>European Psychiatry</i> , <b>2008</b> , 23, 390-5	6	12
280	Further evidence of MAO-A gene variants associated with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2007</b> , 144B, 37-40	3.5	12
279	Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2006</b> , 30, 442-8	5.5	12

278	Lithium long-term treatment in mood disorders: clinical and genetic predictors. <i>Pharmacogenomics</i> , <b>2002</b> , 3, 117-29	2.6	12
277	Dopamine D3 receptor gene not associated with symptomatology of major psychoses <b>1999</b> , 88, 476-480	0	12
276	No association between serotonin-2A receptor gene polymorphism and psychotic symptomatology of mood disorders. <i>Psychiatry Research</i> , <b>1999</b> , 86, 203-9	9.9	12
275	Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. <i>International Clinical Psychopharmacology</i> , <b>1996</b> , 11, 109-117	2.2	12
274	Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. <i>Neuroscience Letters</i> , <b>2020</b> , 726, 133651	3.3	12
273	Manifesto for an international digital mental health network <b>2019</b> , 2, 14-24		11
272	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 94, 109638	<sub>3</sub> 5.5	11
271	The influence of AHI1 variants on the diagnosis and treatment outcome in schizophrenia. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 2517-29	6.3	11
270	Expansion and further delineation of the SETD5 phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance. <i>Clinical Genetics</i> , <b>2018</b> , 93, 752-761	4	11
269	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 172	4.2	11
268	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. <i>Journal of Affective Disorders</i> , <b>2014</b> , 168, 91-7	6.6	11
267	HSP70 polymorphisms in first psychotic episode drug-nalle schizophrenic patients. <i>Life Sciences</i> , <b>2014</b> , 100, 133-137	6.8	11
266	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. <i>Human Psychopharmacology</i> , <b>2014</b> , 29, 388-91	2.3	11
265	5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 131-2	1.7	11
264	Novel antidepressants and panic disorder: evidence beyond current guidelines. <i>Neuropsychobiology</i> , <b>2011</b> , 63, 1-7	4	11
263	Association of SORL1 alleles with late-onset Alzheimer's disease. findings from the GIGAS_LOAD study and mega-analysis. <i>Current Alzheimer Research</i> , <b>2012</b> , 9, 491-9	3	11
262	TAAR 6 and HSP-70 variations associated with bipolar disorder. <i>Neuroscience Letters</i> , <b>2009</b> , 465, 257-61	3.3	11
261	Investigation of an epistastic effect between a set of TAAR6 and HSP-70 genes variations and major mood disorders. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2010</b> , 153B, 680	- <del>हे</del> हुउ	11

260	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2015</b> , 13, 48-52	3.4	11
259	How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2020</b> , 18, 484	<del>49</del> 2	11
258	Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. <i>International Clinical Psychopharmacology</i> , <b>2020</b> , 35, 233-242	2.2	11
257	Personalized and precision medicine as informants for treatment management of bipolar disorder. <i>International Clinical Psychopharmacology</i> , <b>2019</b> , 34, 189-205	2.2	11
256	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. <i>Biological Psychiatry</i> , <b>2021</b> ,	7.9	11
255	The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder. <i>Advances in Therapy</i> , <b>2017</b> , 34, 713-724	4.1	10
254	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 89, 97-104	5.2	10
253	Predominant polarity in bipolar disorder patients: The COPE bipolar sample. <i>Journal of Affective Disorders</i> , <b>2019</b> , 250, 43-50	6.6	10
252	The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades. <i>Journal of Affective Disorders</i> , <b>2016</b> , 190, 429-43	<b>6</b> .6	10
251	Influence of differentially expressed genes from suicide post-mortem study on personality traits as endophenotypes on healthy subjects and suicide attempters. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2014</b> , 264, 423-32	5.1	10
250	Effects of antipsychotic drugs on insight in schizophrenia. <i>Psychiatry Research</i> , <b>2014</b> , 218, 20-4	9.9	10
249	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 43-58	4.3	10
248	Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms. <i>Neuropsychobiology</i> , <b>2010</b> , 62, 61-71	4	10
247	Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 variations does not impact alcohol dependence disorder features. <i>International Journal of Environmental Research and Public Health</i> , <b>2009</b> , 6, 1980-90	4.6	10
246	NCAM1, TACR1 and NOS genes and temperament: a study on suicide attempters and controls. <i>Neuropsychobiology</i> , <b>2011</b> , 64, 32-7	4	10
245	Factors associated with the course of symptoms in bipolar disorder during a 1-year follow-up: depression vs. sub-threshold mixed state. <i>Nordic Journal of Psychiatry</i> , <b>2011</b> , 65, 419-26	2.3	10
244	Antipsychotic response in the first week predicts later efficacy. <i>Neuropsychobiology</i> , <b>2012</b> , 66, 100-5	4	10
243	Cognitive Status, Depressive Symptoms, and Health Status as Predictors of Functional Disability Among Elderly Persons With Low-to-Moderate Education: The Faenza Community Aging Study. <i>American Journal of Geriatric Psychiatry</i> , <b>2005</b> , 13, 672-685	6.5	10

242	Seasonal variations of lithium plasma levels. <i>Psychiatry Research</i> , <b>2002</b> , 111, 35-41	9.9	10
241	Effects of SORL1 gene on Alzheimer's disease. Focus on gender, neuropsychiatric symptoms and pro-inflammatory cytokines. <i>Current Alzheimer Research</i> , <b>2013</b> , 10, 154-64	3	10
240	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. <i>American Journal of Medical Genetics Part A</i> , <b>2002</b> , 114, 177-85		10
239	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , <b>2013</b> , 150, 649-52	6.6	9
238	Alcohol Dependence and Genetic Variability in the Serotonin Pathway among Currently and Formerly Alcohol-Dependent Males. <i>Neuropsychobiology</i> , <b>2015</b> , 72, 57-64	4	9
237	Possible influence of CREB1, CREBBP and CREM variants on diagnosis and treatment outcome in patients with schizophrenia. <i>Neuroscience Letters</i> , <b>2012</b> , 508, 37-41	3.3	9
236	Generalized tonic-clonic seizure secondary to duloxetine poisoning: a short report with favorable out come. <i>NeuroToxicology</i> , <b>2012</b> , 33, 189-90	4.4	9
235	The impact of adverse life events on clinical features and interaction with gene variants in mood disorder patients. <i>Psychopathology</i> , <b>2013</b> , 46, 384-9	3.4	9
234	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. <i>Psychiatry Research</i> , <b>2011</b> , 188, 166-9	9.9	9
233	Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2011</b> , 31, 345-8	1.7	9
232	Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. <i>Clinical Drug Investigation</i> , <b>2010</b> , 30, 187-93	3.2	9
231	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. <i>Psychiatry Research</i> , <b>2010</b> , 178, 430-2	9.9	9
230	TPH2 gene variants and anxiety during alcohol detoxification outcome. <i>Psychiatry Research</i> , <b>2009</b> , 167, 106-14	9.9	9
229	Social adjustment could be associated with the serotonin transporter gene in remitted patients with mood disorders and healthy subjects. <i>Psychiatry Research</i> , <b>2005</b> , 134, 191-4	9.9	9
228	Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. <i>Neuroscience Letters</i> , <b>2006</b> , 406, 107-12	3.3	9
227	No interaction between serotonin transporter gene and dopamine receptor D4 gene in symptomatology of major psychoses <b>1999</b> , 88, 481-485		9
226	Pharmacogenetics and Depression: A Critical Perspective. <i>Psychiatry Investigation</i> , <b>2019</b> , 16, 645-653	3.1	9
225	Abelson helper integration site-1 gene variants on major depressive disorder and bipolar disorder. <i>Psychiatry Investigation</i> , <b>2014</b> , 11, 481-6	3.1	9

224	Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 41, 70-80	1.2	9
223	Biallelic variants in FBXL3 cause intellectual disability, delayed motor development and short stature. <i>Human Molecular Genetics</i> , <b>2019</b> , 28, 972-979	5.6	9
222	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 108, 110170	5.5	9
221	Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. <i>Advances in Therapy</i> , <b>2018</b> , 35, 1656-1670	4.1	9
220	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , <b>2017</b> , 20, 782-787	5.8	8
219	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 27-31	1.7	8
218	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. <i>Psychiatry Research</i> , <b>2014</b> , 215, 799-800	9.9	8
217	Investigation of epistasis between DAOA and 5HTR1A variants on clinical outcomes in patients with schizophrenia. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2013</b> , 17, 504-7	1.6	8
216	Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR(?)D) trial. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 1739-46	1.2	8
215	Pharmacogenetics of antidepressants and mood stabilizers. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 106, 715-44	3	8
214	Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study. <i>Clinical Drug Investigation</i> , <b>2011</b> , 31, 385-405	3.2	8
213	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. <i>Psychiatry Research</i> , <b>2010</b> , 179, 222-5	9.9	8
212	Schizophrenia: genetics, prevention and rehabilitation. <i>Acta Neuropsychiatrica</i> , <b>2009</b> , 21, 109-20	3.9	8
211	Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. <i>Annals of General Psychiatry</i> , <b>2007</b> , 6, 5	3.4	8
210	Ethical problems in pharmacogenetic studies of psychiatric disorders. <i>Pharmacogenomics Journal</i> , <b>2006</b> , 6, 289-95	3.5	8
209	Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. <i>Human Psychopharmacology</i> , <b>2004</b> , 19, 25-9	2.3	8
208	CRY1 Variations Impacts on the Depressive Relapse Rate in a Sample of Bipolar Patients. <i>Psychiatry Investigation</i> , <b>2015</b> , 12, 118-24	3.1	8
207	Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for and. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2019</b> , 17, 364-368	3.4	8

206	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. <i>Neuropsychobiology</i> , <b>2016</b> , 73, 160-8	4	8
205	Genetic variability in tryptophan hydroxylase 2 gene in alcohol dependence and alcohol-related psychopathological symptoms. <i>Neuroscience Letters</i> , <b>2015</b> , 604, 86-90	3.3	7
204	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. <i>International Journal of Neuroscience</i> , <b>2015</b> , 125, 336-43	2	7
203	Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. <i>Neuropsychobiology</i> , <b>2017</b> , 76, 209-221	4	7
202	A Genetic Dissection of Antipsychotic Induced Movement Disorders. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 312-330	4.3	7
201	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2009</b> , 150B, 434-8	3.5	7
200	Epistasis between a set of variations located in the TAAR6 and HSP-70 genes toward schizophrenia and response to antipsychotic treatment. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 806-11	1.2	7
199	Metabolic side effects of second generation antipsychotic agents in antipsychotic-nalle patients: one-month prospective evaluation. <i>Psychiatry Research</i> , <b>2008</b> , 157, 269-71	9.9	7
198	Genetics and pharmacogenetics of mood disorders. <i>Psychiatria Polska</i> , <b>2017</b> , 51, 197-203	1.3	7
197	No association of a set of candidate genes on haloperidol side effects. <i>PLoS ONE</i> , <b>2012</b> , 7, e44853	3.7	7
196	Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. <i>Psychiatry Investigation</i> , <b>2016</b> , 13, 247-9	3.1	7
195	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2020</b> , 99, 109835	5.5	7
194	Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , <b>2016</b> , 370, 162-166	3.2	7
193	High occupational level is associated with poor response to treatment of depression. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 1320-6	1.2	7
192	Association between CANCA1C gene rs1034936 polymorphism and alcohol dependence in bipolar disorder. <i>Journal of Affective Disorders</i> , <b>2020</b> , 261, 181-186	6.6	7
191	Precision psychiatry in clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2021</b> , 25, 19-27	2.4	7
190	Further evidence supporting the association between the dopamine receptor D2 Ser/Cys311 variant and disorganized symptomatology of schizophrenia. <i>Schizophrenia Research</i> , <b>2000</b> , 43, 161-2	3.6	7
189	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 120, 482-490	3.1	6

188	Alzheimer's Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. <i>Neuropsychobiology</i> , <b>2019</b> , 78, 79-85	4	6
187	Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 89, 23-29	5.5	6
186	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. <i>Neuropsychobiology</i> , <b>2015</b> , 72, 118-25	4	6
185	Case-control association study of GRIA1, GRIA2 and GRIA4 polymorphisms in bipolar disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2012</b> , 16, 18-26	2.4	6
184	Investigation of possible epistatic interactions between GRIA2 and GRIA4 variants on clinical outcomes in patients with major depressive disorder. <i>Journal of International Medical Research</i> , <b>2013</b> , 41, 809-15	1.4	6
183	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2011</b> , 35, 74-7	5.5	6
182	Excessive daytime sleepiness in depressed women. <i>Psychiatry Research</i> , <b>2010</b> , 179, 171-5	9.9	6
181	Further evidence supporting the association between 5HTR2C gene and bipolar disorder. <i>Psychiatry Research</i> , <b>2010</b> , 180, 151-2	9.9	6
180	No association between genetic markers in BDNF gene and lithium prophylaxis in a Greek sample. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2010</b> , 14, 154-7	2.4	6
179	Tyrosine hydroxylase and DOPA decarboxylase gene variants in personality traits. <i>Neuropsychobiology</i> , <b>2009</b> , 59, 23-7	4	6
178	Bipolar disorder: "pure" versus mixed depression over a 1-year follow-up. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2012</b> , 16, 113-20	2.4	6
177	Influence of TAAR6 polymorphisms on response to aripiprazole. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2009</b> , 33, 822-6	5.5	6
176	Self-esteem in remitted patients with mood disorders is not associated with the dopamine receptor D4 and the serotonin transporter genes. <i>Psychiatry Research</i> , <b>1998</b> , 80, 137-44	9.9	6
175	Personality and Genetics. Current Psychiatry Reviews, 2007, 3, 147-159	0.9	6
174	Depression and social phobia secondary to alcohol dependence. <i>Neuropsychobiology</i> , <b>2007</b> , 56, 111-8	4	6
173	Outcome of affective psychosis <b>1999</b> , 10, 50-54		6
172	Lack of association between tryptophan hydroxylase gene and psychotic symptomatology in schizophrenia. <i>Schizophrenia Research</i> , <b>1999</b> , 40, 171-2	3.6	6
171	"Separation" of the mother-child couple: pregnancy and maternity of drug-dependent women. <i>Acta Paediatrica, International Journal of Paediatrics</i> , <b>1994</b> , 404, 47-53	3.1	6

170	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , <b>2019</b> , 49, 49-54	6.9	6
169	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 104, 110050	5.5	6
168	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , <b>2018</b> , 33, e2682	2.3	6
167	A genetic dissection of antipsychotic induced movement disorders. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 312-30	4.3	6
166	Deiodinases, Organic Anion Transporter Polypeptide Polymorphisms, and Thyroid Hormones in Patients with Myocardial Infarction. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2018</b> , 22, 270-278	1.6	5
165	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , <b>2018</b> , 227, 254-259	6.6	5
164	Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders. <i>Metabolic Brain Disease</i> , <b>2016</b> , 31, 183-9	3.9	5
163	Modulation of a number of genes on personality traits in a sample of healthy subjects. <i>Neuroscience Letters</i> , <b>2014</b> , 566, 320-5	3.3	5
162	Temperamental and genetic predictors of suicide attempt and self-mutilation. <i>Neuropsychobiology</i> , <b>2013</b> , 68, 250-7	4	5
161	Clozapine augmentation with amisulpride. Journal of Psychiatry and Neuroscience, 2014, 39, E38-9	4.5	5
160	Genomewide interaction and enrichment analysis on antidepressant response. <i>Psychological Medicine</i> , <b>2014</b> , 44, 753-65	6.9	5
159	DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder. <i>Journal of International Medical Research</i> , <b>2012</b> , 40, 258-65	1.4	5
158	Serotonin transporter gene variants and prediction of stress-induced risk for psychological distress. <i>Genes, Brain and Behavior</i> , <b>2011</b> , 10, 536-41	3.6	5
157	No influence of FAT polymorphisms in response to aripiprazole. <i>Journal of Human Genetics</i> , <b>2010</b> , 55, 32-6	4.3	5
156	Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre case-control study. <i>Psychiatric Genetics</i> , <b>2006</b> , 16, 169-71	2.9	5
155	VNTR polymorphism of tyrosine hydroxylase gene and schizophrenia in the Korean population. <i>Neuropsychobiology</i> , <b>2003</b> , 47, 131-6	4	5
154	DRD4 exon 3 variants are not associated with symptomatology of major psychoses in a German population. <i>Neuroscience Letters</i> , <b>2004</b> , 368, 269-73	3.3	5
153	Low-dose buprenorphine detoxification in long term methadone addicts. <i>Regulatory Peptides</i> , <b>1994</b> , 53, S289-S290		5

152	Serotonin transporter gene (5-HTTLPR) and major psychoses		5
151	Cortico-limbic functional connectivity mediates the effect of early life stress on suicidality in bipolar depressed 5-HTTLPR*s carriers. <i>Journal of Affective Disorders</i> , <b>2020</b> , 263, 420-427	6.6	5
150	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 1821-1829	8.7	5
149	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	5
148	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , <b>2021</b> , 38, 896-906	8.4	5
147	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. Journal of Affective Disorders, <b>2019</b> , 249, 410-417	6.6	5
146	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. <i>Neuropsychobiology</i> , <b>2019</b> , 77, 67-72	4	5
145	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , <b>2013</b> , 25, 97-106	1.4	5
144	Maoa and Maob polymorphisms and personality traits in suicide attempters and healthy controls: a preliminary study. <i>Psychiatry Research</i> , <b>2017</b> , 249, 212-217	9.9	4
143	Nine differentially expressed genes from a post mortem study and their association with suicidal status in a sample of suicide completers, attempters and controls. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 91, 98-104	5.2	4
142	The brief assessment of cognition in affective disorders: Normative data for the Italian population. Journal of Affective Disorders, <b>2019</b> , 252, 245-252	6.6	4
141	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , <b>2020</b> , 720, 134754	3.3	4
140	The black sheep of the family- whole-exome sequencing in family of lithium response discordant bipolar monozygotic twins. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 34, 19-27	1.2	4
139	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. <i>Journal of Molecular Neuroscience</i> , <b>2018</b> , 64, 273-286	3.3	4
138	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , <b>2014</b> , 55, 51-5	7.3	4
137	Benefit of slow titration of paroxetine to treat depression in the elderly. <i>Human Psychopharmacology</i> , <b>2014</b> , 29, 544-51	2.3	4
136	Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients. <i>Neuropsychobiology</i> , <b>2014</b> , 69, 76-82	4	4
135	Quetiapine extended release: preliminary evidence of a rapid onset of the antidepressant effect in bipolar depression. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 303-6	1.7	4

134	DAOA variants and schizophrenia: influence on diagnosis and treatment outcomes. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2011</b> , 15, 303-10	2.4	4	
133	S.17.05 Molecular genetics of bipolar disorders: Implication for psychotropic drugs. <i>European Neuropsychopharmacology</i> , <b>1997</b> , 7, S112-S113	1.2	4	
132	Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. <i>Current Medicinal Chemistry</i> , <b>2008</b> , 15, 2472-517	4.3	4	
131	. Psychiatric Genetics, <b>2003</b> , 13, 121-126	2.9	4	
130	Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder. <i>Psychiatry Investigation</i> , <b>2008</b> , 5, 102-5	3.1	4	
129	Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2020</b> , 18, 231-240	3.4	4	
128	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder		4	
127	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2020</b> , 270, 901-910	5.1	4	
126	Pharmacogenetic-Guided Treatment of Depression: Real-World Clinical Applications, Challenges, and Perspectives. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 573-581	6.1	4	
125	Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 109, 110266	5.5	4	
124	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , <b>2021</b> ,		4	
123	Analysis of depressive symptomatology in mood disorders. <i>Depression and Anxiety</i> , <b>1998</b> , 8, 80-5	8.4	4	
122	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , <b>2014</b> , 26, 243-53	1.4	4	
121	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. <i>Advances in Therapy</i> , <b>2017</b> , 34, 1482-1497	4.1	3	
120	A model to investigate SNPs' interaction in GWAS studies. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 145-53	4.3	3	
119	Antagonist and partial agonist at the dopamine D2 receptors in drug-naMe and non-drug-naMe schizophrenia: a randomized, controlled trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2015</b> , 265, 579-88	5.1	3	
118	A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. <i>Journal of Neural Transmission</i> , <b>2015</b> , 122, 465-75	4.3	3	
117	Impact of 5-HTTLPR polymorphism on alexithymia in alcoholic patients after detoxification treatment. <i>Journal of Addiction Medicine</i> , <b>2013</b> , 7, 372-3	3.8	3	

116	No influence of DTNBP1 polymorphisms on the response to aripiprazole. <i>Neuropsychobiology</i> , <b>2010</b> , 62, 245-9	4	3
115	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 55, 86-95	1.2	3
114	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts		3
113	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , <b>2021</b> , 286, 149-157	6.6	3
112	Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. <i>Molecular Biology Reports</i> , <b>2020</b> , 47, 191-200	2.8	3
111	Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. <i>Journal of Molecular Neuroscience</i> , <b>2018</b> , 64, 62-74	3.3	3
110	Melancholic features in major depression - a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 110, 110285	5.5	3
109	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 141, 167-175	5.2	3
108	High occupational level is associated with poor response to the treatment of depression: A replication study. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 349-355	1.2	2
107	Serum Aripiprazole Concentrations Prehemodialysis and Posthemodialysis in a Schizophrenic Patient With Chronic Renal Failure: A Case Report. <i>Journal of Clinical Psychopharmacology</i> , <b>2020</b> , 40, 200	o <del>-1</del> 202	2
106	Social adjustment among treatment responder patients with mood disorders. <i>Journal of Affective Disorders</i> , <b>2013</b> , 150, 961-6	6.6	2
105	Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 565-9	1.7	2
104	P.3.c.055 Clozapine resistance: augmentation strategies. <i>European Neuropsychopharmacology</i> , <b>2011</b> , 21, S500	1.2	2
103	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. <i>Psychopharmacology</i> , <b>2011</b> , 214, 719-28	4.7	2
102	Analysis of requirements and specifications for a monitoring system to support the self-management of dementia patients at home <b>2010</b> ,		2
101	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries European Archives of Psychiatry and Clinical Neuroscience, 2022, 1	5.1	2
100	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study <i>European Neuropsychopharmacology</i> , <b>2022</b> , 56, 100-111	1.2	2
99	The search for personalized antidepressant treatments: what have we learned and where are we going. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 1095-1100	2.6	2

98	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review <i>European Neuropsychopharmacology</i> , <b>2022</b> , 55, 112-157	1.2	2
97	The Use of DNA Microarray in the Pharmacogenetics of Antidepressants: Guidelines for a Targeted Approach. <i>Current Genomics</i> , <b>2004</b> , 5, 499-508	2.6	2
96	The neuropsychological hypothesis of antidepressant drug action revisited. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2014</b> , 13, 1722-39	2.6	2
95	Antidepressants: Indications, Contraindications, Interactions, and Side Effects <b>2020</b> , 1-38		2
94	Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders and known risk fac	ctors	2
93	Genetic underpinnings of sociability in the UK Biobank		2
92	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2020</b> , 23, 571-577	5.8	2
91	Genetic underpinnings of sociability in the general population. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 1	628 <del>./</del> 16	342
90	Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 1-8	3.8	2
89	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , <b>2021</b> , 279, 722-729	6.6	2
88	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2021</b> , 19, 46-52	3.4	2
87	A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2021</b> , 19, 160-165	3.4	2
86	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder <b>2000</b> , 96, 136		2
85	No interaction of GABA(A) alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. <i>American Journal of Medical Genetics Part A</i> , <b>1999</b> , 88, 44-9		2
84	Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. <i>American Journal of Medical Genetics Part A</i> , <b>2000</b> , 96, 84-7		2
83	Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence <i>International Clinical Psychopharmacology</i> , <b>2021</b> , 37,	2.2	2
82	Persistent benefits of slow titration of paroxetine in a six-month follow-up. <i>Human Psychopharmacology</i> , <b>2015</b> , 30, 329-33	2.3	1
81	P.1.a.007 Four polymorphisms of SLC6A4 are novel predictors of SSRI/SNRI response in depressive disorder: sequencing analysis of SLC6A4. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, S162-S163	1.2	1

80	Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs <b>2016</b> , 39-54		1
79	Is Pharmacogenetics Useful in Antidepressant Treatment?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 916-918	6.1	1
78	Genetics of Treatment-resistant Depression <b>2013</b> , 43-90		1
77	Low-activity alleles of the MAOA gene are associated with measures of hostility. <i>Psychiatric Genetics</i> , <b>2015</b> , 25, 215	2.9	1
76	P.1.a.006 CACNA1C gene and schizophrenia: A case-control and pharmacogenetic study. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, S162	1.2	1
75	Pharmacogenomics of Depression. Advances in Biological Psychiatry, 2010, 58-74		1
74	No influence of SLC6A3 40 base VNTR polymorphism on the response to risperidone. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2010</b> , 14, 228-32	2.4	1
73	Genetics of Mood Disorders <b>2005</b> , 35-75		1
72	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 114, 110480	5.5	1
71	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> ,	5.8	1
70	Genome-Wide Association Identifies the First Risk Loci for Psychosis in Alzheimer Disease		1
69	Epistatic Interactions between CREB and CREM Variants in Affective Disorder. <i>Psychiatry Investigation</i> , <b>2014</b> , 11, 200-3	3.1	1
68	The association of childhood trauma, lifetime stressful events and general psychopathological symptoms in euthymic bipolar patients and healthy subjects. <i>Journal of Affective Disorders</i> , <b>2021</b> , 289, 66-73	6.6	1
67	Irritable Mood and Subthreshold Hypomanic Episodes Correlate with More Severe Major Depression. <i>Neuropsychobiology</i> , <b>2021</b> , 80, 425-436	4	1
66	Brexpiprazole: a step forward for precision medicine in resistant depression. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1817-1819	4	1
65	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , <b>2021</b> , 28, 4296-4320	4.3	1
64	Seasonality in Major Depressive Disorder: Effect of Sex and Age. <i>Journal of Affective Disorders</i> , <b>2022</b> , 296, 111-116	6.6	1
63	Pharmacogenetics of Antidepressant Response <b>2008</b> , 315-353		1

62	Dopamine D2 receptor gene not associated with symptomatology of mood disorders. <i>American Journal of Medical Genetics Part A</i> , <b>1999</b> , 88, 294-7		1
61	Outcome of affective psychosis. <i>Depression and Anxiety</i> , <b>1999</b> , 10, 50-4	8.4	1
60	Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders <i>Translational Psychiatry</i> , <b>2022</b> , 12, 59	8.6	1
59	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 60, 91-99	1.2	1
58	FKBP5 Gene Variants May Modulate Depressive Features in Bipolar Disorder. <i>Neuropsychobiology</i> , <b>2019</b> , 78, 104-112	4	O
57	22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders. <i>Lancet Psychiatry,the</i> , <b>2018</b> , 5, 531-532	23.3	0
56	Reply to Comments by Dr Rico-Villademoros. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 99	1.7	Ο
55	Genetics of Mood Disorders <b>2009</b> , 125-133		O
54	Mindfulness-Based Cognitive Therapy vs. Psycho-education for Patients with Anxiety Disorders Who Did Not Achieve Remission Following Adequate Pharmacological Treatment. <i>Mindfulness</i> , <b>2021</b> , 12, 2059-2075	2.9	0
53	Switch to 3-Month Long-Acting Injectable Paliperidone May Decrease Plasma Levels: A Case Series. Journal of Clinical Psychopharmacology, <b>2021</b> , 41, 694-696	1.7	O
52	Precision medicine in mood disorders <b>2022</b> , 1,		0
51	Imputed expression of schizophrenia-associated genes and cognitive measures in patients with schizophrenia <i>Molecular Genetics &amp; Enomic Medicine</i> , <b>2022</b> , e1942	2.3	O
50	Depression, antidepressants, and insulin resistance: which link?. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 60, 4-6	1.2	0
49	The U-shaped relationship between parental age and the risk of bipolar disorder in the offspring: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 60, 55-75	1.2	O
48	The influence of the serotonin transporter gene 5-HTTLPR polymorphism on suicidal behavior: a meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, S278-S279	1.2	
47	Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, S378-S379	1.2	
46	Il trattamento antidepressivo: effetti sul peso corporeo. <i>L Endocrinologo</i> , <b>2015</b> , 16, 22-25	О	
45	P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, S159-S160	1.2	

Highlights on Pharmacogenetics and Pharmacogenomics in Depression **2018**, 3-16

43	Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?. Evidence-Based Mental Health, 2016, 19, e25	11.1
42	P.3.d.026 Pharmacogenetics of clozapine response and metabolic side effects: a comprehensive review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S536-S537	1.2
41	P.6.b.002 Oxidative stress and expression of alcohol related psychopathological symptoms in alcohol dependent subjects. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S664	1.2
40	P.3.018 Insomnia and somnolence induced by second-generation antidepressants during the treatment of major depression: a meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S69-S70	) 1.2
39	Highlights from the latest articles in suicide research. <i>Personalized Medicine</i> , <b>2014</b> , 11, 255-258	2.2
38	P1.a.023 Impact of a SNP in SIGMAR1 on major depression, bipolar disorder and treatment response. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, S170-S171	1.2
37	P.1.a.034 Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease: a systematic review. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, S175-S176	1.2
36	P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, S540-S541	1.2
35	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, S168-S169	1.2
34	P.2.f.025 Specificity profile of venlafaxine and sertraline in major depression: meta-regression of double-blind, randomized clinical trials. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, S409-S410	1.2
33	Authors' reply to "Recommendations for conducting mindfulness based cognitive therapy trials". <i>Psychiatry Research</i> , <b>2013</b> , 207, 232-3	9.9
32	Prescribing patterns of psychiatric drugs in major depressive disorder Findings from a large European multicenter, cross-sectional study. <i>European Psychiatry</i> , <b>2017</b> , 41, S367-S367	6
31	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, S583	1.2
30	Potential genes behind the difference between bipolar I and bipolar II disorder. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, S836-S837	1.2
29	Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, S1057-S1058	1.2
28	Gene-Environment Interaction Studies in Suicidal Behaviour. Advances in Biological Psychiatry,63-74	
27	Pharmacogenetics of Antidepressant Drugs <b>2014</b> , 543-562	

# (2016-2014)

26	The genetics of vascular incidents associated with second-generation antipsychotic administration. <i>Expert Review of Clinical Pharmacology</i> , <b>2014</b> , 7, 75-90	3.8
25	P.2.a.011 Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, S230	1.2
24	P.3.c.044 Influence of ANKK1 and DRD2 gene polymorphisms in response to haloperidol. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, S342	1.2
23	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. <i>European Psychiatry</i> , <b>2011</b> , 26, 1833-1833	6
22	Clock genes and mood disorders: Which role?. European Psychiatry, 2011, 26, 2136-2136	6
21	E.02.02 Pitfalls, problems and future. European Neuropsychopharmacology, <b>2011</b> , 21, S233-S234	1.2
20	P.2.c.026 Rapid versus slow titration of paroxetine antidepressant treatment in elderly population: an observational study. <i>European Neuropsychopharmacology</i> , <b>2011</b> , 21, S397-S398	1.2
19	P.2.e.025 Bipolar depression: quetiapine extended release effectiveness. <i>European Neuropsychopharmacology</i> , <b>2011</b> , 21, S432	1.2
18	Are Noradrenergic Antidepressants a Valuable Choice in the Treatment of Panic Disorder? A Review and Meta Analysis. <i>European Psychiatry</i> , <b>2009</b> , 24, 1-1	6
17	Corrigendum to: IIAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study[[Eur Psychiatr 2008;23:3908]. <i>European Psychiatry</i> , <b>2009</b> , 24, 64-64	6
16	P.1.a.006 Serotonin transporter: an example of gene influence on human behaviour. <i>European Neuropsychopharmacology</i> , <b>2008</b> , 18, S205-S206	1.2
15	P.1.a.007 A genetic assessment of antipsychotic and antidepressant cardiac iatrogenicity: focus on the proarrhythmic profile. <i>European Neuropsychopharmacology</i> , <b>2008</b> , 18, S206	1.2
14	Major depressive disorders: depressive disorders <b>2006</b> , 45-73	
13	S.03.05 Clinical pharmacogenetic studies in the treatment of depression. <i>European Neuropsychopharmacology</i> , <b>2006</b> , 16, S169	1.2
12	Psychopathology of dysthymia. <i>European Psychiatry</i> , <b>1998</b> , 13, 258s-258s	6
11	Adaptacifi social y autoestima en pacientes con remisifi de trastorno del estado de filmo. <i>European Psychiatry (Ed Espatola)</i> , <b>2000</b> , 7, 26-32	
10	The Role of Pharmacogenetics in Pharmacovigilance of Psychotropic Drugs <b>2016</b> , 121-146	
9	Practical Application of Pharmacogenetics of Antipsychotic, Antidepressant, and Mood-Stabilizing Drugs <b>2016</b> , 111-117	

8	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, S240-S241	1.2
7	Epidemiology of psychopharmacological options in unipolar major depression in European tertiary psychiatric treatment centers. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, S417-S418	1.2
6	Possible biomarkers modulating haloperidol efficacy and/or tolerability. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 507-29	2.6
5	Attrition in treatment-resistant depression: predictors and clinical impact. <i>International Clinical Psychopharmacology</i> , <b>2019</b> , 34, 161-169	2.2
4	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , <b>2022</b> , 296, 485-492	6.6
3	Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank. <i>Psychological Medicine</i> ,1-9	6.9
2	P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , <b>2021</b> , 53, S646-S647	1.2
1	Interleukin-1 Beta in Peripheral Blood Mononuclear Cell Lysates as a Longitudinal Biomarker of Response to Antidepressants: A Pilot Study <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 801738	5